C Michael Gibson Discussing The Results of The Phase III OCEANIC-STROKE Trial with Mike Sharma
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Mike Sharma and I discuss the results of the phase III OCEANIC-STROKE Trial: In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%.
The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.
There was no increase in mild or severe bleeding or intracranial bleeding
63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy
Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin
All benefit with no increase in bleeding risk
View slides here.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
-
Jun 6, 2026, 15:14Julianne Chong: Components of Antithrombotic Stewardship Programs from an International Perspective
-
Jun 6, 2026, 15:13Vincent Ten Cate: The Largest Blood-Based EWAS of Atherosclerosis to Date